NANDROLONE PHENPROPIONATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NANDROLONE PHENPROPIONATE (NANDROLONE PHENPROPIONATE).

How it works

Nandrolone phenpropionate is an anabolic steroid that binds to androgen receptors, activating gene expression leading to increased protein synthesis, nitrogen retention, and muscle growth. It also exhibits weak androgenic activity and may inhibit glucocorticoid receptors.

What the body does with it

Metabolism	Primarily hepatic via reduction and conjugation (glucuronidation and sulfation). Metabolites include 19-norandrosterone and 19-noretiocholanolone. CYP450 enzyme involvement is minimal.
Excretion	Primarily renal (90% as metabolites, mainly glucuronide and sulfate conjugates; 6% as unchanged drug); about 4% fecal.
Half-life	Terminal elimination half-life approximately 8-10 hours, but active metabolite 19-nortestosterone has a longer half-life (~2-4 hours), necessitating frequent dosing for stable blood levels.
Protein binding	Extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound in circulation.
Volume of Distribution	Vd: 1.3-1.8 L/kg, indicating extensive tissue binding and distribution into muscle and other tissues.
Bioavailability	IM: 100% after intramuscular injection (oil-based depot); negligible oral bioavailability due to extensive first-pass metabolism.
Onset of Action	IM: Onset of anabolic effects within 24-48 hours; peak plasma levels reached in 24-48 hours.
Duration of Action	IM: Duration of clinical effect (e.g., erythropoiesis stimulation) is about 2-3 weeks due to depot formation, but single dose effects persist for 1-2 weeks.

Classification & Brands

Dosing & administration

100-200 mg intramuscularly every 2-3 weeks.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment; use with caution in moderate impairment with dose reduction based on clinical response.
Liver impairment	Contraindicated in Child-Pugh class B and C; use with caution in class A with dose reduction.
Pediatric use	Not recommended for pediatric use; safety and efficacy not established.
Geriatric use	Use with caution; lower starting doses due to potential for increased sensitivity and comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NANDROLONE PHENPROPIONATE (NANDROLONE PHENPROPIONATE).

Breastfeeding	Excreted in breast milk; M/P ratio unknown. May cause androgenic effects in nursing infants. Contraindicated during breastfeeding.
Teratogenic Risk	First trimester: Androgenic effects may cause fetal virilization (clitoromegaly, labial fusion) in female fetuses. Second/third trimester: Continued risk of virilization; potential for premature epiphyseal closure and growth retardation. Contraindicated in pregnancy.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: ANABOLIC STEROIDS CAN CAUSE PELIOSIS HEPATIS (PURPURA OF THE LIVER) AND HEPATIC CELL TUMORS. ALSO, PROLONGED USE MAY LEAD TO AORTIC RUPTURE, SUDDEN DEATH, OR CORONARY ARTERY DISEASE. NOT FOR USE IN WOMEN OF CHILDBEARING POTENTIAL OR PREGNANT WOMEN.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to nandrolone or any component; pregnancy; breastfeeding; carcinoma of the breast or prostate; severe hepatic dysfunction; hypercalcemia; nephrotic syndrome; and patients with known or suspected coronary artery disease.

Clinical Precautions

Precautions

Hepatotoxicity (peliosis hepatis, hepatic tumors), cardiovascular risks (hyperlipidemia, hypertension, arrhythmias), dyslipidemia, insulin resistance, premature closure of epiphyseal growth plates, virilization in women, gynecomastia, and males may experience decreased spermatogenesis and impotence. Monitor liver function, lipid profile, and renal function.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NANDROLONE PHENPROPIONATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NANDROLONE PHENPROPIONATE (NANDROLONE PHENPROPIONATE).

How it works

What the body does with it

Metabolism	Primarily hepatic via reduction and conjugation (glucuronidation and sulfation). Metabolites include 19-norandrosterone and 19-noretiocholanolone. CYP450 enzyme involvement is minimal.
Excretion	Primarily renal (90% as metabolites, mainly glucuronide and sulfate conjugates; 6% as unchanged drug); about 4% fecal.
Half-life	Terminal elimination half-life approximately 8-10 hours, but active metabolite 19-nortestosterone has a longer half-life (~2-4 hours), necessitating frequent dosing for stable blood levels.
Protein binding	Extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound in circulation.
Volume of Distribution	Vd: 1.3-1.8 L/kg, indicating extensive tissue binding and distribution into muscle and other tissues.
Bioavailability	IM: 100% after intramuscular injection (oil-based depot); negligible oral bioavailability due to extensive first-pass metabolism.
Onset of Action	IM: Onset of anabolic effects within 24-48 hours; peak plasma levels reached in 24-48 hours.
Duration of Action	IM: Duration of clinical effect (e.g., erythropoiesis stimulation) is about 2-3 weeks due to depot formation, but single dose effects persist for 1-2 weeks.

Classification & Brands

Dosing & administration

100-200 mg intramuscularly every 2-3 weeks.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment; use with caution in moderate impairment with dose reduction based on clinical response.
Liver impairment	Contraindicated in Child-Pugh class B and C; use with caution in class A with dose reduction.
Pediatric use	Not recommended for pediatric use; safety and efficacy not established.
Geriatric use	Use with caution; lower starting doses due to potential for increased sensitivity and comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NANDROLONE PHENPROPIONATE (NANDROLONE PHENPROPIONATE).

Breastfeeding	Excreted in breast milk; M/P ratio unknown. May cause androgenic effects in nursing infants. Contraindicated during breastfeeding.
Teratogenic Risk	First trimester: Androgenic effects may cause fetal virilization (clitoromegaly, labial fusion) in female fetuses. Second/third trimester: Continued risk of virilization; potential for premature epiphyseal closure and growth retardation. Contraindicated in pregnancy.
Fetal Monitoring